rood blauwe elepsis logo Belegger.nl
Uitgebreid zoeken

Guru Terug naar discussie overzicht

***** GNBT *******

3.572 Posts
Pagina: «« 1 ... 147 148 149 150 151 ... 179 »» | Laatste | Omlaag ↓
  6. [verwijderd] 30 juli 2007 12:11

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    het is al weer een hele tijd geleden dat we echt goed nieuws hebben gekregen , het wordt tijd zou ik zeggen :)

    aankondiging start fase III bijvoorbeeld :)
  12. [verwijderd] 31 juli 2007 14:31

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    The International Journal of Cancer Publishes Studies on the Anti-Cancer Activity of Generex Biotechnology's Immunotherapeutic Vaccine
    Tuesday July 31, 8:00 am ET


    WORCESTER, Mass., July 31, 2007 (PRIME NEWSWIRE) -- Generex Biotechnology Corporation (NasdaqCM:GNBT - News) announced today publication in the peer-reviewed International Journal of Cancer (published online Jul 16, 2007) of studies demonstrating the anti-tumor activity of its novel Ii-Key/HER-2/neu immunotherapeutic vaccine as well as mechanistic explanations for the enhancements observed using this proprietary vaccine. The studies were conducted as part of a collaboration between the Cancer Immunology and Immunotherapy Center, Saint Savas Cancer Hospital, Athens, Greece and Antigen Express, Inc., the immunotherapeutic subsidiary of Generex. The article was authored by Ioannis F. Voutsas, Angelos D. Gritzapis, Louisa G. Mahaira, Maria Salagianni, Eric von Hofe, Nikoletta L. Kallinteris, and Constantin N. Baxevanis.
    ADVERTISEMENT


    The International Journal of Cancer publishes material under a broad scope of topics relevant to experimental and clinical cancer research. Its readership is comprised of cancer physicians and investigators, epidemiologists, virologists, immunologists, oncologists, and occupational and environmental health scientists.

    The publication, entitled ``Induction of potent CD4+ cell-mediated responses by a helper HER-2/neu peptide linked to the Ii-Key moiety of the invariant chain'', presents studies showing how the proprietary portion of the immunotherapeutic vaccine enhances the potency of peptide vaccines. Specifically, the modification developed by Antigen Express increases the interaction time between the peptide vaccine and T helper cells, thereby enhancing specific stimulation against the HER-2/neu peptide. The further studies show that T helper cells stimulated by the vaccine increase the length of time tumor-infiltrating lymphocytes exhibit anti-tumor activity.

    The HER-2/neu vaccine being developed by Antigen Express (AE37) is currently in Phase II clinical trials in patients with breast cancer. Those studies are being conducted in conjunction with United States Military Cancer Institute's Clinical Trials Group under a Clinical Trial Agreement. The same compound will also be investigated in patients with HER-2/neu-positive prostate cancer. Patients for those trials have been selected and dosing is expected to begin before the fall of 2007. The latter trial will be conducted as an extension of the collaboration between Antigen Express and the Saint Savas Cancer Hospital.

    ``Our recent studies further establish the scientific underpinnings of the Antigen Express technology in general and for the clinical development of AE37 in particular,'' said Dr. Eric von Hofe, President of Antigen Express. ``Publication in the International Journal of Cancer demonstrates the thoroughness and scientific rigor that goes into the development of Antigen Express products.''

    In addition to the development of immunotherapeutic cancer vaccines, Antigen Express is also developing vaccines for infectious diseases. A Phase I trial of a peptide vaccine for use against the potentially pandemic H5N1 avian influenza virus, developed using the same technology used for AE37, was recently initiated. The particular advantage of Antigen Express vaccine technology for preparation against bird flu is that it relies on the use of synthetic peptides, which can be manufactured more rapidly and in larger amounts than traditional vaccines.

    About Generex

3.572 Posts
Pagina: «« 1 ... 147 148 149 150 151 ... 179 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Belegger.nl

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.017
AB InBev 2 5.499
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 51.665
ABO-Group 1 22
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 265
Accsys Technologies 23 10.667
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 189
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.752
Aedifica 3 916
Aegon 3.258 322.845
AFC Ajax 538 7.088
Affimed NV 2 6.297
ageas 5.844 109.893
Agfa-Gevaert 14 2.050
Ahold 3.538 74.337
Air France - KLM 1.025 35.045
AIRBUS 1 12
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.041
Alfen 16 24.851
Allfunds Group 4 1.473
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 406
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.822
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.837 243.229
AMG 971 133.349
AMS 3 73
Amsterdam Commodities 305 6.690
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 491
Antonov 22.632 153.605
Aperam 92 15.007
Apollo Alternative Assets 1 17
Apple 5 382
Arcadis 252 8.776
Arcelor Mittal 2.033 320.712
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.302
Aroundtown SA 1 219
Arrowhead Research 5 9.739
Ascencio 1 28
ASIT biotech 2 697
ASMI 4.108 39.108
ASML 1.766 107.395
ASR Nederland 21 4.486
ATAI Life Sciences 1 7
Atenor Group 1 491
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.673
Axsome Therapeutics 1 177
Azelis Group 1 64
Azerion 7 3.392